Tehran Darou Pharmaceutical Company (DETEHRAN) income statement
Operating revenue through to net profit and earnings per share
- Ticker
- DETEHRAN
- Industry
- Pharmaceuticals
- Market
- IFB Base Market
Latest periods
| Item | To 1404/12/29 | To 1403/12/30 | To 1402/12/29 | To 1401/12/29 | To 1400/12/29 | To 1399/12/30 |
|---|---|---|---|---|---|---|
| Operating revenue | 21,551,672 | 12,647,149 | 9,976,758 | 6,255,335 | 4,221,732 | 2,285,248 |
| Cost of operating revenue | -10,470,238 | -7,905,748 | -5,919,074 | -4,100,244 | -3,157,621 | -1,761,971 |
| Gross profit (loss) | 11,081,434 | 4,741,401 | 4,057,684 | 2,155,091 | 1,064,111 | 523,277 |
| Selling, general and administrative expenses | -941,259 | -639,705 | -494,377 | -299,958 | -215,748 | -145,150 |
| Other expenses | -12,612 | -91 | -827 | -2,067 | -319 | -203 |
| Operating profit (loss) | 10,127,563 | 4,101,605 | 3,562,480 | 1,853,066 | 848,044 | 377,924 |
| Finance costs | -1,864,622 | -1,197,932 | -1,222,659 | -629,308 | -416,806 | -169,885 |
| Other non-operating income and expenses | 553,442 | 109,118 | 62,935 | 389,202 | 182,453 | 69,995 |
| Profit (loss) from continuing operations before tax | 8,816,383 | 3,012,791 | 2,402,756 | 1,612,960 | 613,691 | 278,034 |
| Current year tax | -1,654,772 | -465,401 | -210,378 | -108,791 | -69,820 | -31,366 |
| Net profit (loss) from continuing operations | 7,161,611 | 2,547,390 | 2,192,378 | 1,444,343 | 543,871 | 237,223 |
| Net profit (loss) | 7,161,611 | 2,547,390 | 2,192,378 | 1,444,343 | 543,871 | 237,223 |
| Basic earnings (loss) per share | 3,892 rials | 1,384 rials | 1,192 rials | 2,675 rials | 9,065 rials | 3,954 rials |
| Net earnings (loss) per share, rials | 3,893 rials | 1,385 rials | 1,192 rials | 2,675 rials | 9,065 rials | 3,954 rials |
| Capital | 1,840,000 | 1,840,000 | 1,840,000 | 540,000 | 60,000 | 60,000 |
Reporting periods
72 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1405/07/07.